- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT05939128
Uno studio prospettico non interventistico sul carcinoma mammario ad alto rischio HER2-negativo precoce e sulla prevalenza delle mutazioni BRCA1/2 in Russia (ERA)
Uno studio multicentrico, a braccio singolo, non interventistico, osservazionale e prospettico per valutare la prevalenza di BRCA1/2m, gli approcci terapeutici e gli esiti nelle pazienti con carcinoma mammario in fase iniziale ad alto rischio HER2 in Russia
(Neo)adjuvant treatment approaches and outcomes
Panoramica dello studio
Stato
Condizioni
Tipo di studio
Iscrizione (Effettivo)
Contatti e Sedi
Luoghi di studio
-
-
-
Arkhangelsk, Russia
- Research Site
-
Barnaul, Russia
- Research Site
-
Belgorod, Russia
- Research Site
-
Chelyabinsk, Russia
- Research Site
-
Grozny, Russia
- Research Site
-
Irkutsk, Russia
- Research Site
-
Khanty-Mansiysk, Russia
- Research Site
-
Krasnodar, Russia
- Research Site
-
Krasnoyarsk, Russia
- Research Site
-
Moscow, Russia
- Research Site
-
Nal'chik, Russia
- Research Site
-
Nyzhny Novgorod, Russia
- Research Site
-
Ryazan, Russia
- Research Site
-
Saint Petersburg, Russia
- Research Site
-
Severodvinsk, Russia
- Research Site
-
Sochi, Russia
- Research Site
-
Ufa, Russia
- Research Site
-
Vladivostok, Russia
- Research Site
-
Yaroslavl, Russia
- Research Site
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Study population will consist of early breast cancer HER2-negative patients with high risk of recurrence with available medical history, surgery or biopsy FFPE from primary tumor. It is estimated that approximately 750 patients will be enrolled in approximately 25 sites
Descrizione
Inclusion Criteria:
-
Patients aged ≥ 18 years old
-. Signed ICF, including patient's consent for genetic testing specimens from primary tumor and blood samples
-
Early HER2-negative BC (stages 2 and 3)
-
Compliance with at least 1 of the criteria for BRCA1/2 testing in accordance with the clinical guidelines of the Ministry of Health of the Russian Federation
-
Unknown BRCAm status or negative BRCAm PCR test
-
Performed surgical treatment (not more than 7 months before inclusion)
-. High risk of recurrence according to one or more criteria:
- incomplete pathomorphological response (in case of neoadjuvant therapy)
- CPS-EG 3 scale score 3 and more (in case of neoadjuvant therapy)
- presence of ≥ 4 metastatic lymph nodes in HR+ pts (in case of only adjuvant therapy)
- ≥pT2 or ≥pN1 in TNBC pts (in case of only adjuvant therapy)
- Any other high risk criterion according to investigators opinion
-
The presence of postoperative or biopsy FFPE
Exclusion Criteria:
- Participation in another clinical study with an investigational product during the last 3 months
- Confirmation that the subject was already included in this study before
- Absence of a written informed consent form; Data erroneously collected from subjects for which written consent is not available, will not be included in or will be deleted from the study database
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Modelli osservazionali: COHORT
- Prospettive temporali: PROSPECTIVE
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
The primary objective of this study is to determine the prevalence of germline and somatic BRCA1/2 mutations in high-risk early HER2-negative breast cancer
Lasso di tempo: 3 years
|
The prevalence of germline and somatic BRCA1/2 mutations in high-risk early HER2-negative breast cancer will be presented as a number of missing and non-missing records, median, standard deviation, 95% confidence interval for median |
3 years
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
To describe treatment approaches of high-risk early HER2-negative breast cancer in routine practice in the general population, in the BRCAm and non-BRCAm population
Lasso di tempo: 3 years
|
Demographics, clinical characteristics, and treatment approaches will be summarized using descriptive statistics. |
3 years
|
|
To determine invasive disease-free survival for high-risk early HER2-negative breast cancer in the general population, in the BRCAm and non-BRCAm population
Lasso di tempo: 3 years
|
The Kaplan-Meier method will be used to estimate the median (95% CI) IDFS and OS for the total sample and all subgroups. Cumulative survival curves will be created using Kaplan-Meier analysis |
3 years
|
|
To determine 3-year OS for high-risk early HER2-negative breast cancer in the general population, in the BRCAm and non-BRCAm population
Lasso di tempo: 3 years
|
The Kaplan-Meier method will be used to estimate the median (95% CI) IDFS and OS for the total sample and all subgroups. Cumulative survival curves will be created using Kaplan-Meier analysis |
3 years
|
|
To determine the prevalence of HRR mutations in HER2-negative breast cancer
Lasso di tempo: 3 years
|
Testing the archived tumour specimen and blood for BRCA1/2m and HRRm status |
3 years
|
|
To determine invasive disease-free survival in the HRRm population (including BRCA1/2)
Lasso di tempo: 3 years
|
Testing the archived tumour specimen and blood for BRCA1/2m and HRRm status |
3 years
|
|
To evaluate concordance between P53 expression and BRCAm
Lasso di tempo: 3 years
|
Testing the archived tumour specimen and blood |
3 years
|
|
To assess the quality of life in patients with various types of adjuvant systemic therapy
Lasso di tempo: 3 years
|
completed WHOQOL-BREF questionnaire will be assessed |
3 years
|
Collaboratori e investigatori
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- D133HR00030
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .